OCEANSIDE, Calif., Oct. 18, 2018 /PRNewswire/ — AOTI Inc. announced today that it will participate at Jefferies 2018 London Healthcare Conference, being held on November 14 and 15, 2018 in London, United Kingdom.
Now in its ninth year, the Jefferies conference is the largest healthcare-dedicated conference in Europe, hosting over 400 participating companies, 1,800 attendees and 4,500 business-to-business and investor meetings. The event will feature leading public and private companies from the pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors from the United States, Europe, Africa, Middle East, Latin America, Russia, India, Israel, China and Japan.
This global gathering of leading healthcare executives and institutional, private equity and venture capital investors will address near and long-term investment opportunities and discuss the mechanisms driving global healthcare.
Link to the conference website: https://www.jefferies.com/OurFirm/Conferences/325/413
Additionally, AOTI announced that it will present at the 3rd annual INV€$TIVAL Showcase in partnership with Jefferies, being held on November 13, 2018 in London, United Kingdom.
Biotech and Money connects corporates to capital and the event is the most direct way of showcasing the latest innovative and investable private and public life science opportunities to their investor network.
In exclusive partnership with Jefferies LLC, the INV€$TIVAL Showcase spans 4-tracks and will feature the most exciting companies across key sub-sectors within life sciences, including immuno-oncology, neuroscience & CNS, cell and gene therapies, digital health and medtech.
Link to the conference website: https://www.lsxleaders.com/investival-showcase
AOTI Inc. is a privately owned company based in Oceanside, California USA and Galway, Ireland, that provides innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating illnesses. Our patented non-invasive Topical Wound Oxygen (TWO2) therapy is unsurpassed in fully closing Diabetic, Venous and Pressure ulcers alike.
For more information see: www.aotinc.net
Dr. Mike Griffiths
CEO and President
(760) 672 1920